Capital Asset Advisory Services’s iShares Biotechnology ETF IBB Stock Holding History

Capital Asset Advisory Services’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16	Closed	-$2K	–	412
2022 Q3	$2K	Sell	16 -11	-41%	-$1.37K	﹤0.01%	435
2022 Q2	$3K	Hold	27	–	–	﹤0.01%	531
2022 Q1	$4K	Hold	27	–	–	﹤0.01%	518
2021 Q4	$4K	Sell	27 -640	-96%	-$99.1K	﹤0.01%	552
2021 Q3	$108K	Buy	667 +7	+1%	+$1.18K	0.01%	453
2021 Q2	$108K	Buy	660 +53	+9%	+$8.16K	0.01%	480
2021 Q1	$91K	Buy	607 +374	+161%	+$59.4K	0.01%	470
2020 Q4	$35K	Buy	233 +15	+7%	+$2.14K	0.01%	696
2020 Q3	$30K	Buy	218 +12	+6%	+$1.63K	0.01%	404
2020 Q2	$27K	Buy	206 +189	+1,112%	+$24.1K	0.01%	434
2020 Q1	$2K	Hold	17	–	–	﹤0.01%	479
2019 Q4	$2K	Buy	+17	New	+$1.9K	﹤0.01%	568

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CANY

Caxton Associates (New York) New York $3.18B AUM 54.49% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Capital Asset Advisory Services's IBB Position: Q4 2022 in Review

Capital Asset Advisory Services sold out of iShares Biotechnology ETF (IBB) in Q4 2022, closing a stake of 16 shares — an estimated $2K sold.

Capital Asset Advisory Services first reported a position in IBB in Q4 2019 and held it in 12 quarters. The position peaked at $108K in Q3 2021. 902 funds tracked by Wall St. Rank hold IBB as of Q4 2022.

Capital Asset Advisory Services reported no remaining iShares Biotechnology ETF position as of Q4 2022 after selling out during the quarter.
Capital Asset Advisory Services sold 16 iShares Biotechnology ETF shares in Q4 2022, an estimated $2K.
Capital Asset Advisory Services first reported a position in iShares Biotechnology ETF in Q4 2019 and held it in 12 quarters.
Capital Asset Advisory Services's iShares Biotechnology ETF position peaked at $108K in Q3 2021.
902 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2022.

Based on Capital Asset Advisory Services's 13F filing for Q4 2022, filed 8 Mar 2023.